Autoimmune Diseases  >>  talmapimod (SCIO-469)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
talmapimod (SCIO-469) / J&J
NCT00043732: Safety Study of SCIO-469 to Treat Patients With Active Rheumatoid Arthritis Receiving Methotrexate

Completed
2
120
US
SCIO-469
Scios, Inc.
Rheumatoid Arthritis
 
09/03
NCT00089921: SPRiNG: SCIO-469 Patients With Rheumatoid Arthritis Not Receiving Methotrexate

Completed
2
302
US
SCIO-469, Placebo
Scios, Inc.
Arthritis, Rheumatoid
 
10/05

Download Options